Taysha Gene Therapies, Inc.
TSHA
$4.06
-$0.37-8.35%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -338.82% | 18.90% | 26.47% | 19.96% | 89.38% |
| Total Depreciation and Amortization | -12.01% | -13.84% | -11.87% | -9.19% | -4.39% |
| Total Amortization of Deferred Charges | -83.04% | -- | -- | -- | -- |
| Total Other Non-Cash Items | 133.98% | -61.76% | -65.20% | -64.48% | -128.09% |
| Change in Net Operating Assets | 93.88% | 33.27% | -36.20% | 30.79% | -197.01% |
| Cash from Operations | -7.14% | -8.97% | -14.89% | -11.24% | -87.33% |
| Capital Expenditure | -23.66% | -15.36% | -461.47% | 90.33% | 93.62% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1,928.57% | 102.35% | 100.52% | 100.32% | 100.20% |
| Cash from Investing | 10.88% | 91.38% | 83.46% | 95.06% | 96.03% |
| Total Debt Issued | 26.05% | -- | -- | -- | -- |
| Total Debt Repaid | 5.55% | -- | -- | -- | -- |
| Issuance of Common Stock | 179.86% | 5.57% | -45.26% | -45.31% | -57.75% |
| Repurchase of Common Stock | -26.00% | 14.89% | 14.89% | 14.89% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 54.06% | 67.54% | 52.72% | 77.83% | 40.42% |
| Cash from Financing | 208.65% | 7.56% | -43.94% | -43.78% | -59.98% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,207.38% | 9.71% | -112.21% | -108.75% | -105.10% |